Form 4: Alnylam Exec's Stock Vest & Tax-Related Sale

Alnylam Pharmaceuticals' EVP, Chief Commercial Officer, Tolga Tanguler, acquired shares through PSU vesting and subsequently sold a portion to cover tax obligations.

Summary

• Tolga Tanguler, EVP, Chief Commercial Officer of Alnylam Pharmaceuticals, Inc. (ALNY), acquired 2,851 shares of common stock on October 1, 2025, at a price of $0.0 per share.
• This acquisition resulted from the vesting of 30% of performance-based stock units (PSUs) granted on March 1, 2024, triggered by the public reporting of a Phase 3 clinical study initiation in a prevalent indication.
• Following the vesting, Tanguler's direct beneficial ownership increased to 28,843 shares.
• On October 2, 2025, a total of 1,505 shares of common stock were automatically sold by the company on behalf of Mr. Tanguler.
• These sales were executed at weighted average prices ranging from $446.53 to $457.43 per share.
• The sales were mandatory 'sell-to-cover' transactions to satisfy minimum statutory tax withholding obligations associated with the PSU vesting.
• After these sales, Mr. Tanguler's direct beneficial ownership stands at 27,438 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The core event is the vesting of performance-based stock units, which signifies the achievement of a significant clinical development milestone (Phase 3 initiation). While there was a sale of shares, it was non-discretionary and for tax purposes, not a reflection of management's discretionary view on the stock's future.

Positives

• The vesting of performance-based stock units indicates the achievement of a significant corporate milestone: the public reporting of the initiation of a Phase 3 clinical study in a prevalent indication.
• The initiation of a Phase 3 clinical study is a positive development for a pharmaceutical company, signaling progress in its drug development pipeline.

Negatives

• A total of 1,505 shares were sold, which reduces the direct beneficial ownership of a key executive, although these sales were non-discretionary for tax purposes.

Future Outlook

The vesting of performance-based stock units was contingent upon the public reporting of the initiation of a Phase 3 clinical study in a prevalent indication, indicating progress in the company's clinical development pipeline.

Industry Context

For a pharmaceutical company like Alnylam, the initiation of a Phase 3 clinical study is a critical and often value-driving milestone, signifying that a drug candidate has progressed through earlier development stages and is now being tested in a larger patient population to confirm efficacy and safety before potential regulatory submission.

Stakeholder Impact

• Shareholders: The vesting of PSUs indicates the company is meeting its strategic clinical development goals, which could be viewed positively. The tax-related sale is a routine event for executives receiving equity compensation.
• Employees: The compensation structure for executives, including performance-based incentives, is demonstrated, potentially impacting employee morale and retention strategies.

Next Steps

• Continued progress and reporting on the Phase 3 clinical study initiated by the issuer.

Key Dates

Recommendation

This Form 4 primarily details a routine insider transaction involving the vesting of performance-based stock units and a subsequent non-discretionary sale to cover tax obligations. While the underlying trigger for the PSU vesting (Phase 3 clinical study initiation) is a positive operational milestone for Alnylam, the transaction itself does not provide new fundamental information that would warrant a change in investment recommendation. It reflects compensation mechanics rather than a discretionary investment decision by the executive. Therefore, a 'hold' recommendation is appropriate as the filing does not present a compelling reason to alter an existing position based solely on this information.

Keywords

Alnylam Pharmaceuticals, ALNY, Form 4, Insider Transaction, Performance Stock Units, PSU Vesting, Tax Withholding, Phase 3 Clinical Study, Biotechnology, Pharmaceuticals